Mink to provide second quarter 2023 financial report and corporate update

New york, july 28, 2023 (globe newswire) -- mink therapeutics (nasdaq: inkt), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release before the market opens on thursday, aug. 10.
INKT Ratings Summary
INKT Quant Ranking